Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

MLA

Ricci, Sergio, et al. “Clinical Benefit of Bone-Targeted Radiometabolic Therapy with 153Sm-EDTMP Combined with Chemotherapy in Patients with Metastatic Hormone-Refractory Prostate Cancer.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 34, no. 7, July 2007, pp. 1023–30. EBSCOhost, https://doi.org/10.1007/s00259-006-0343-8.

APA

Ricci, S., Boni, G., Pastina, I., Genovesi, D., Cianci, C., Chiacchio, S., Orlandini, C., Grosso, M., AlSharif, A., Chioni, A., Donato, S., Francesca, F., Selli, C., Rubello, D., & Mariani, G. (2007). Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. European Journal of Nuclear Medicine & Molecular Imaging, 34(7), 1023–1030. https://doi.org/10.1007/s00259-006-0343-8

Chicago

Ricci, Sergio, Giuseppe Boni, Ilaria Pastina, Dario Genovesi, Claudia Cianci, Serena Chiacchio, Cinzia Orlandini, et al. 2007. “Clinical Benefit of Bone-Targeted Radiometabolic Therapy with 153Sm-EDTMP Combined with Chemotherapy in Patients with Metastatic Hormone-Refractory Prostate Cancer.” European Journal of Nuclear Medicine & Molecular Imaging 34 (7): 1023–30. doi:10.1007/s00259-006-0343-8.